This section features insightful audio commentary from a multidisciplinary group of experts in interstitial lung disease. Faculty address clinically relevant topics identified by IPF experts.

Amy Olson, MD, MSPH discusses emerging treatments for IPF, the mechanisims and prospects

Play


cme-ce
Maria L. Padilla, MD, and Timothy P. M. Whelan, MD
discuss inhaled NAC as treatment for ipf?

Play


cme-ce
Maria L. Padilla, MD, and Timothy P. M. Whelan, MD
discuss efficacy, safety, and current evidence on combining nintedanib and pirfenidone


Harold Collard, MD and Steven Nathan, MD, FCCP discuss the following:

  • Non-pharmacologic approaches to disease management

Play


cme-ce
David J. Lederer, MD, MS, and Ganesh Raghu, MD, FACP, FCCP
discuss the recent ATS guidelines.

Upon completion of this course, the participants should be able to:

  • Discuss the efficacy, safety, and clinical application of new treatment options in patients with IPF

Harold Collard, MD and Steven Nathan, MD, FCCP discuss using antifibrotic drugs for patients with IPF:

  • Real-world complexities of pharmacologic treatment
  • Disease progression, switching, and drug combinations

Play


James P. Lamberti, MD discusses the National Association for Medical Director of Respiratory Care (NAMDRC):

  • Description of the conference
  • The history and mission of NAMDRC
  • Anticipated results from NAMDRC 2016 in Ranch Mirage, California

 

 

 

Play


David J. Lederer, MD, MS, and Ganesh Raghu, MD, FACP, FCCP discuss the following topics:

  • Exciting news from ATS 2015
  • Anticipated results from ATS 2016

Play


p2p-icon(small)
    LISTEN to
Dr. Marilyn Glassberg and Dr. Charlie Strange's debate


 glassberg  

Listen to Dr. Glassberg and Dr. Strange discuss how they choose a treatment for a patient with IPF. Using a pro/con format, they address the efficacy, safety, and side effects of new drugs and the important role comorbidities play when making treatment decisions.

Play


Steven D. Nathan, MD, Athol U. Wells, MD, and Rajan Saggar, MD discuss the following:

  • What are the signs and symptoms that a patient with IIP might have PH
  • Studies from 2014 positive takeaways, limitations, and lessons learned
  • Clinical trials

Steven D. Nathan, MD, Athol U. Wells, MD, and Rajan Saggar, MD discuss the following:

  • What are the implications if patients with IIPs have PH?
  • PH in IIP: driver of outcomes or surrogate of severe disease?


The PILOT Expert Faculty summarize the latest IPF Publications. Current topics include:

  • The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
  • Increasing global mortality from Idiopathic Pulmonary Fibrosis in the 21st century

Maria L. Padilla, MD, Steven A. Sahn, MD and Charlie Strange, MD discuss the following:

  • Which CTDs should be included in a differential diagnosis of progressive dyspnea and restrictive lung disease?
  • What are the important serologic markers and when can they appear?
  • Are IPF and CTD mutually exclusive or can they be comorbidities?

Kevin O. Leslie, MD, Imre Noth, MD and Glenn D. Rosen, MD discuss the following:

  • What are the diagnostic criteria for IPF?
  • What is the clinical profile consistent with IPF?
  • When should a diagnosis other than IPF be considered with a finding of UIP?

Steven D. Nathan, MD, Maria L. Padilla, MD and Glenn D. Rosen, MD discuss the following:

  • Describe the 2010 CAPACITY trials. What were the study designs, results, and implications for clinical practice?

Imre Noth, MD, Maria L. Padilla, MD and Charlie Strange, MD discuss the following:

  • What are the most effective ways to help patients change their lifestyles? Are there preferred tools for smoking cessation, weight loss, diet management, etc?
  • How much do patients want to know about IPF and what are the best sources of information?
  • What are the biggest concerns of patients with IPF and how can we address them?

Harold R. Collard, MD, Kevin R. Flaherty, MD and Steven A. Sahn, MD discuss the following:

  • Which tests are the most useful for monitoring IPF? Which are best for assessing the effects of therapy and which are most prognostic? Are there tests that can predict acute exacerbations of IPF?
  • What are the emerging molecular markers which enhance diagnosis or prognosis?
  • What is the role of patient self-assessment in management of IPF and which tools are best?

Dr. Kevin Flaherty, MD, FCCP answers common questions related to the newly approved treatments for IPF.

Access other Therapeutic Areas: